Gain Therapeutics
GANX
35 hedge funds and large institutions have $11.9M invested in Gain Therapeutics in 2025 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 11 increasing their positions, 5 reducing their positions, and 4 closing their positions.
120% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 5
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
44% more capital invested
Capital invested by funds: $8.24M → $11.9M (+$3.61M)
6% more funds holding
Funds holding: 33 → 35 (+2)
2.54% more ownership
Funds ownership: 10.11% → 12.65% (+2.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$517K |
| 2 |
Jones Financial Companies
Des Peres,
Missouri
|
+$461K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$264K |
| 4 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$222K |
| 5 |
Renaissance Technologies
New York
|
+$174K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DIG
Dauntless Investment Group
Etna,
New Hampshire
|
-$147K |
| 2 |
Morgan Stanley
New York
|
-$43K |
| 3 |
QC
Quadrature Capital
London,
United Kingdom
|
-$38.3K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$27.4K |
| 5 |
SI
Sprott Inc
Toronto,
Ontario, Canada
|
-$26.7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Group One Trading
Chicago,
Illinois
| $11.5K | +$11.8K | +6,401 | New |
|
27
Simplex Trading
Chicago,
Illinois
| $10K | +$4.09K | +2,213 | +64% |
|
|
CAM
28
Creekmur Asset Management
Morton,
Illinois
| $7.99K | – | – | – |
|
|
MCM
29
MAI Capital Management
Independence,
Ohio
| $7.94K | – | – | – |
|
30
Bank of America
Charlotte,
North Carolina
| $7.5K | +$115 | +62 | +2% |
|
31
Wells Fargo
San Francisco,
California
| $4.77K | – | – | – |
|
|
AAP
32
Arax Advisory Partners
Denver,
Colorado
| $4.5K | – | – | – |
|
33
Raymond James Financial
St Petersburg,
Florida
| $4.14K | +$4.25K | +2,300 | New |
|
|
SOW
34
State of Wyoming
Cheyenne,
Wyoming
| $2.15K | +$2.21K | +1,194 | New |
|
|
TRCT
35
Tower Research Capital (TRC)
New York
| $1.7K | -$2.75K | -1,487 | -61% |
|
|
QC
36
Quadrature Capital
London,
United Kingdom
| – | -$38.3K | -20,154 | Closed |
|
|
TSS
37
Two Sigma Securities
New York
| – | -$27.4K | -14,355 | Closed |
|
|
SI
38
Sprott Inc
Toronto,
Ontario, Canada
| – | -$26.7K | -14,000 | Closed |
|
39
Fidelity Investments
Boston,
Massachusetts
| – | -$154 | -80 | Closed |
|
GANX Hedge Fund Activity: Q2 2025 in Review
35 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Gain Therapeutics (GANX) for Q2 2025, worth a combined $11.9M — up 44% from $8.24M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new GANX positions and 4 closed out — a net gain of 2 holders — while 11 added to existing stakes and 5 trimmed.
The largest buyer was Vanguard Group, adding an estimated $517K. The largest seller was Dauntless Investment Group, cutting an estimated $147K.
- 35 institutional investors held Gain Therapeutics (GANX) as of Q2 2025, up from 33 in Q1 2025.
- Funds reported $11.9M of Gain Therapeutics stock for Q2 2025, up 44% quarter-over-quarter.
- 6 funds opened new Gain Therapeutics positions in Q2 2025 and 4 closed out, a net change of +2 holders.
- The largest Gain Therapeutics buyer in Q2 2025 was Vanguard Group, an estimated $517K added.
- The largest Gain Therapeutics seller in Q2 2025 was Dauntless Investment Group, an estimated $147K sold.
Based on aggregated 13F filings for Q2 2025.